Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.03
-0.85 (-3.16%)
Feb 11, 2026, 1:16 PM EST - Market open
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$929,617
Profits / Employee
-$129,602
Market Cap
3.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | 54 | 25 | 86.21% |
| Sep 30, 2020 | 53 | 26 | 96.30% |
| Jun 30, 2020 | 49 | 28 | 133.33% |
| Mar 31, 2020 | 43 | 22 | 104.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Denali Therapeutics | 517 |
| Xenon Pharmaceuticals | 327 |
| Vera Therapeutics | 224 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 181 |
| Liquidia | 170 |
| Edgewise Therapeutics | 136 |
ARQT News
- 5 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis - GlobeNewsWire
- 16 days ago - Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa - GlobeNewsWire
- 19 days ago - Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference - GlobeNewsWire
- 21 days ago - Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions - GlobeNewsWire
- 4 weeks ago - Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones - GlobeNewsWire
- 2 months ago - Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - GlobeNewsWire
- 2 months ago - Arcutis Biotherapeutics: The Earnings Inflection Has Arrived - Seeking Alpha